Suritozole

Suritozole

Suritozole
Systematic (IUPAC) name
5-(3-fluorophenyl)-2,4-dimethyl-2,4-dihydro-3H-1,2,4-triazole-3-thione
Clinical data
Legal status
?
Identifiers
CAS number  YesY
ATC code None
PubChem
ChemSpider  N
UNII  YesY
KEGG  YesY
Chemical data
Formula C10H10FN3S 
Mol. mass 223.269 g/mol
 N   

Suritozole (MDL 26,479) is an investigational cognition enhancer. It acts as a partial inverse agonist at the benzodiazepine receptor site on the GABAA ion channel complex, but does not have either anxiogenic or convulsant effects, unlike other BZD inverse agonists such as DMCM.[1] It was investigated for the treatment of depression and Alzheimer's disease,[2] but clinical development seems to have been discontinued.

Synthesis

Suritozole synthesis: Lednicer book 6.

References

  1. ^ Miller JA, Dudley MW, Kehne JH, Sorensen SM, Kane JM (September 1992). "MDL 26,479: a potential cognition enhancer with benzodiazepine inverse agonist-like properties". Br. J. Pharmacol. 107 (1): 78–86.  
  2. ^ Robbins DK, Hutcheson SJ, Miller TD, Green VI, Bhargava VO, Weir SJ (May 1997). "Pharmacokinetics of MDL 26479, a novel benzodiazepine inverse agonist, in normal volunteers". Biopharm Drug Dispos 18 (4): 325–34.